2024
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingPatient-derived-xenograftsBase excision repairCopy number lossMultiregion whole-exome sequencingCopy number gainHigh-grade neuroendocrine carcinomaCNV analysisPhylogenetic analysisEvolutionary historyNeuroendocrine cervical cancerHuman papillomavirus DNAMutator phenotypeSensitivity to afatinibGenetic landscapeRecurrent mutationsRNA sequencingGene fusionsMutational landscape analysisExcision repairGenesMutationsPan-HERConsistent with deficiencyNeuroendocrine carcinomaRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaAntibody-dependent cellular cytotoxicityT-DXdUSC patientsUSC cell linesTrastuzumab deruxtecanSerous carcinomaHER2 expressionClinical trialsRecurrent uterine serous carcinomaTopoisomerase I inhibitor payloadSignificant antibody-dependent cellular cytotoxicityCell linesMultiple tumor indicationsPrimary USC cell linesLow HER2 expressionFuture clinical trialsHigh recurrence ratePeripheral blood lymphocytesERBB2 gene amplificationGrowth suppressionHER2-overexpressing cell linesTumor growth suppressionOverall survivalStandard chemotherapyHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife dataEffectiveness of telehealth physical therapy for patients with pelvic floor disorders in a community hospital setting
Coad B, Ramani S, Michel L, Peled A, Morgan J, Hartnett J, Chudnoff S, Andikyan V. Effectiveness of telehealth physical therapy for patients with pelvic floor disorders in a community hospital setting. Archives Of Gynecology And Obstetrics 2023, 308: 661-665. PMID: 37268794, PMCID: PMC10238233, DOI: 10.1007/s00404-023-07078-6.Peer-Reviewed Original ResearchConceptsTraditional office visitsOffice visitsTelehealth visitsTelehealth physical therapyMethodsRetrospective chart reviewPrimary outcome measureCommunity hospital settingNumber of patientsPelvic floor disordersPhysical therapy patientsSignificant differencesRace/ethnicityChart reviewInsurance typeCommunity hospitalTherapy patientsOutcome measuresPhysical therapyTreatment goalsHospital settingShow visitsPatientsNumber/typeCohortDemographic dataUterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor
McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.Peer-Reviewed Original ResearchConceptsUterine leiomyosarcomaPDX modelsGain of functionMedian overall survivalPhase I trialOral gavage dailyVivo activityTumor growth inhibitionTumor volume differencesTumor cell proliferationOverall survivalTolerable toxicityI trialOral treatmentTreatment cohortsGavage dailyAggressive tumorsSCID miceULMS patientsPK studiesTumor samplesWestern blotCell proliferationControl vehicleLeiomyosarcomaChanges to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic
Sullivan M, Michel L, Wasser T, Clark M, Chudnoff S, Andikyan V. Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic. Journal Of Obstetrics And Gynaecology Research 2023, 49: 1418-1423. PMID: 36808793, DOI: 10.1111/jog.15617.Peer-Reviewed Original ResearchConceptsRate of SDDSame-day dischargeInvasive hysterectomyDay dischargeCOVID-19 pandemicRetrospective chart reviewEmergency department visitsNumber of readmissionsMultivariable logistic regressionSame dayCommon gynecologic proceduresChi-square testChart reviewED visitsDepartment visitsHospital admissionElective surgerySurgical complexityGynecologic proceduresInclusion criteriaNosocomial infectionsHysterectomyPatientsLogistic regressionHealthcare systemThe Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo
Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.Peer-Reviewed Original ResearchConceptsCombination of olaparibOvarian cancerHER2 expressionSingle agentCell linesGynecologic cancer mortalityHER2-negative tumorsOvarian cancer cell linesOvarian cancer patientsEpithelial ovarian carcinomaNovel therapeutic optionsOC cell linesUnmet medical needPoly (ADP-ribose) polymerase (PARP) inhibitorsPan-ErbB inhibitorSingle-agent olaparibPolymerase inhibitor olaparibPoly (ADP-ribose) polymerase (PARP) inhibitor olaparibPrimary HER2Cancer cell linesNegative tumorsTherapeutic optionsCancer mortalityCancer patientsNeu expressionTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.Peer-Reviewed Original ResearchConceptsHER2/neu expressionDS-8201aAntibody-drug conjugatesNeu expressionCS cell linesTrastuzumab deruxtecanOvarian carcinosarcomaTopoisomerase I inhibitor payloadCell linesAggressive gynecologic malignancyLimited therapeutic optionsEffective antibody-drug conjugatesCarcinosarcoma cell lineGynecologic malignanciesTherapeutic optionsIsotype controlSarcomatous elementsXenograft modelBystander killingFlow cytometryTumor cellsCarcinosarcomaAntitumor activityVivo studiesVivo activityCarbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies.
Ramani S, Hartnett J, Karki S, Gallousis S, Clark M, Andikyan V. Carbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2023, 27: e2023.00021. PMID: 37663433, PMCID: PMC10473183, DOI: 10.4293/jsls.2023.00021.Peer-Reviewed Original Research
2022
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor
Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.Peer-Reviewed Original ResearchConceptsHomologous recombination deficiencyCS cell linesCell linesWestern blotKinase inhibitorsOverall animal survivalProtein expressionDose-dependent increaseDose-dependent inhibitionCarcinosarcoma cell lineTumor growth inhibitionCaspase-3 expressionEndometrioid histologyAggressive malignancyUterine carcinosarcomaCS patientsPreclinical activityClinical trialsEpithelial componentAnimal survivalXenograftsApoptosis markersRecombination deficiencyP-ATRP-Chk1Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma
Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsUterine leiomyosarcomaVivo activityVehicle control treatmentMedian overall survivalTumor volume differencesOral scheduleWestern blot analysisOverall survivalOral gavageAggressive malignancyPDX modelsClinical trialsSCID miceTumor measurementsULMS patientsSignificant growth inhibitionNovel ATR inhibitorTumor samplesSignificant toxicityWestern blotKinase inhibitorsATRX mutationsGene mutationsControl vehicle
2012
Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcome
Andikyan V, Khoury-Collado F, Gerst S, Talukdar S, Bochner B, Sandhu J, Abu-Rustum N, Sonoda Y, Barakat R, Chi D. Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcome. Gynecologic Oncology 2012, 126: 346-350. PMID: 22555107, DOI: 10.1016/j.ygyno.2012.04.034.Peer-Reviewed Original ResearchConceptsAnterior pelvic exenterationPelvic exenterationTotal vaginectomyPelvic recurrencePostoperative complicationsGenitourinary malignanciesSurgical techniqueNegative pathologic marginsPreliminary survival dataMajor postoperative complicationsMedian tumor sizeEvidence of diseaseRate of readmissionComplete surgical resectionTotal pelvic exenterationCentral pelvic recurrencePrimary tumor sitePancreatic recurrenceOperative mortalityOncologic outcomesSurgical resectionMedian ageCase seriesPathologic marginsTumor sizeExtended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgery
Andikyan V, Khoury-Collado F, Sonoda Y, Gerst S, Alektiar K, Sandhu J, Bochner B, Barakat R, Boland P, Chi D. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgery. Gynecologic Oncology 2012, 125: 404-408. PMID: 22285844, DOI: 10.1016/j.ygyno.2012.01.031.Peer-Reviewed Original ResearchConceptsExtended pelvic resectionR0 resectionPostoperative complicationsOverall survivalCervical malignancyPelvic resectionPositive pathologic marginsUterus/cervixMajor postoperative complicationsOutcomes of patientsComplete gross resectionKaplan-Meier methodMedian tumor diameterDays post surgeryEn bloc resectionMajor vascular structuresPrimary tumor siteUterus/Perioperative mortalityCommon morbidityGross resectionMedian agePeripheral neuropathyPost surgeryPelvic abscess
2003
Fluoreszenzdiagnostik mit 5-ALA-Thermogel bei zervikaler intraepithelialer Neoplasie
Andikyan V, Kronschnabl M, Hillemanns M, Wang X, Stepp H, Hillemanns P. Fluoreszenzdiagnostik mit 5-ALA-Thermogel bei zervikaler intraepithelialer Neoplasie. Gynäkologische Rundschau 2003, 44: 31-37. PMID: 14673226, DOI: 10.1159/000074315.Peer-Reviewed Original ResearchConceptsCervical intraepithelial neoplasiaNormal adjacent epitheliumCIN 3Female patientsIntraepithelial neoplasiaCIN 1CIN lesionsCervix uteriDysplastic epitheliumHistological examinationAdjacent epitheliumPorphyrin fluorescence intensityNormal ratioTumor selectivityDrug applicationBody temperatureLesionsPhotodynamic therapyGel formulationTwofold increaseEpitheliumEpithelial tissuesMaximal intensityFormulation 4
2000
Morphofunctional changes in the placenta after ozone therapy
Andikyan V, Voloshchuk I, Kovganko P, Clemente J. Morphofunctional changes in the placenta after ozone therapy. Bulletin Of Experimental Biology And Medicine 2000, 130: 715-718. PMID: 11140595, DOI: 10.1007/bf02682114.Peer-Reviewed Original Research